All AbMole products are for research use only, cannot be used for human consumption.
Galeterone (TOK-001, VN/124-1) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively. Galeterone is effective at preventing binding of [3H]-R1881 (methyltrienolone, a stable synthetic androgen) to both the mutant AR (T877A) in LNCaP cells and the wild-type AR in PC-3AR cells. Galeterone potently inhibits the AR-mediated transcription in LNCaP cells transiently transfected with a probasin luciferase reporter construct AARZ-Luc in a concentration-dependent manner. Galeterone inhibits the growth of DHT-stimulated LNCaP and LAPC4 prostate cancer cells with IC50 of <10 μM. Galeterone is very effective at inhibiting the growth of androgen-dependent LAPC4 human prostate tumor xenograft. In the LAPC4 xenograft, Galeterone is a more potent agent in reducing tumor growth than other compounds (VN/85, VN/87, and VN108) and is more effective than castration and casodex. Treatment with Galeterone markedly reduces AR protein levels both in vivo and in vitro. Thus, Galeterone disrupts androgen receptor (AR) signaling via a novel triple mechanism of action (CYP17 inhibition, competitive inhibition, and down-regulation of the AR). Galeterone also inhibits the growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Additionally, Galeterone in combination with thapsigargin exhibits synergistic effect in inhibiting PC-3 cell growth. Galeterone in combination with everolimus or gefitinib demonstrates superior synergy for growth inhibition against hormone-refractory prostate cancer cell line (high-passage LNCaP, HP-LNCaP) compared with bicalutamide. Dual inhibition of AR and mTOR with Galeterone and everolimus acts in concert to reduce tumor growth rates in the castration-resistant prostate cancer xenograft model. Galeterone is a superior inhibitor than abiraterone of R1881-induced transcriptional activity of both wild type and mutant AR.
| Molecular Weight | 388.55 |
| Formula | C26H32N2O |
| CAS Number | 851983-85-2 |
| Solubility (25°C) | DMSO 18 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Androgen Receptor Products |
|---|
| LGD-3303
LGD-3303 is a nonsteroidal, nonaromatizable selective androgen receptor ligand that binds to the androgen receptor with high affinity in a radiolabeled to competitive binding assay (Ki=0.9 nM). |
| Ar-V7-IN-1
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications such as prostate cancer. |
| SC912
SC912 is a potent and selective AR-V7 inhibitor with IC50 of 0.36 μM. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis. |
| A4B17
A4B17 is an androgen receptor N-terminal inhibitor, which can be used for the research of androgen-responsive prostate cancer. |
| AZ'3137
AZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader, with a DC50 value of 22 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
